A81.83 Fatal familial insomnia

Name of the Condition

• Fatal familial insomnia (ICD-10 Code: A81.83)

Summary

Fatal familial insomnia is a rare, inherited prion disease that affects the central nervous system. It is characterized by progressive sleep disturbances, autonomic dysfunction, and cognitive decline. The disease is part of the transmissible spongiform encephalopathies (TSEs), a group of disorders caused by abnormal prion proteins. Fatal familial insomnia primarily involves the thalamus and other brain regions, leading to spongiform changes in neural tissue.

Causes

Fatal familial insomnia is caused by mutations in the PRNP gene, which encodes the prion protein. These mutations lead to the production of abnormal prion proteins that induce misfolding of normal cellular prion proteins in the brain. The disease is inherited in an autosomal dominant pattern, meaning a single copy of the mutated gene is sufficient to cause the condition. Unlike other prion diseases, fatal familial insomnia is not associated with sporadic or acquired transmission.

Risk Factors

• Family history of fatal familial insomnia or other prion diseases
• Inherited mutations in the PRNP gene
• Presence of specific genetic variants associated with the syndrome

Symptoms

• Progressive insomnia, often leading to total sleep deprivation
• Autonomic dysfunction (e.g., hyperhidrosis, tachycardia, hypertension)
• Cognitive decline and memory impairment
• Motor disturbances (e.g., ataxia, myoclonus)
• Hallucinations or delirium in advanced stages

Diagnosis

Diagnosis of fatal familial insomnia involves a combination of clinical evaluation, genetic testing, and imaging studies. Clinical assessment focuses on the characteristic sleep disturbances and neurological symptoms. Genetic testing confirms mutations in the PRNP gene. Imaging, such as MRI, may show thalamic atrophy or other structural changes. Cerebrospinal fluid analysis and prion protein testing may also be used to support the diagnosis.

Treatment Options

There is no cure for fatal familial insomnia. Treatment is supportive and focuses on managing symptoms. Medications may be used to address sleep disturbances, autonomic dysfunction, or cognitive decline. Palliative care is often necessary to improve quality of life in advanced stages. Research into potential therapies is ongoing, but no disease-modifying treatments are currently available.

Prognosis and Follow-Up

Fatal familial insomnia is invariably fatal, with a rapid progression of symptoms. The average survival time after onset is typically 7 to 18 months. Follow-up care involves regular monitoring of neurological and autonomic symptoms, as well as support for patients and their families. Genetic counseling is recommended for affected individuals and their relatives.

Complications

• Severe sleep deprivation leading to cognitive and physical decline
• Autonomic instability, increasing the risk of cardiovascular events
• Progressive neurological deterioration, including motor and cognitive impairment
• Respiratory failure in advanced stages

Lifestyle & Prevention

There are no known preventive measures for fatal familial insomnia, as it is an inherited condition. Genetic counseling and testing are recommended for individuals with a family history of the disease. Supportive care, including sleep hygiene and symptom management, may help improve quality of life during the course of the illness.

When to Seek Professional Help

Seek medical attention if you or a family member experiences persistent insomnia, especially when accompanied by neurological symptoms such as ataxia, cognitive decline, or autonomic dysfunction. Early evaluation is important for accurate diagnosis and management. Genetic counseling should be considered for individuals with a family history of prion diseases.

Tips for Medical Coders

When coding for fatal familial insomnia (A81.83), ensure the diagnosis is confirmed by genetic testing or clinical criteria. Document the presence of PRNP gene mutations and any associated neurological symptoms. Include details of family history or genetic counseling if applicable. Avoid using this code for sporadic or acquired prion diseases, as they are coded separately. Verify that the code aligns with the patient’s clinical presentation and diagnostic workup.